CMPS
COMPASS Pathways plc6.39
-0.20-3.03%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
613.55MP/E (TTM)
-Basic EPS (TTM)
-2.72Dividend Yield
0%Recent Filings
8-K
Jonas joins Compass board
Compass Pathways appointed Dr. Jeffrey Jonas, a seasoned neuroscience leader from Sage Therapeutics and Cure Ventures, to its board effective October 29, 2025, bolstering expertise as COMP360 advances toward potential commercialization. This move coincides with Thomas Lönngren's planned retirement on December 31, 2025, after six years of service guiding clinical progress. Dr. Jonas receives an initial option for 52,000 shares vesting over three years, plus annual cash retainers. His insights sharpen the push for innovative mental health treatments amid regulatory uncertainties.
8-K
COMP360 Phase 3 success
Compass Pathways hit a milestone with its first Phase 3 trial of COMP360 psilocybin for treatment-resistant depression, showing highly significant symptom reduction at six weeks after a single dose, with no unexpected safety issues. The second trial enrolls steadily, eyeing 26-week data in late 2026, while the company probes accelerated FDA filing paths. Cash at $221.9 million funds operations into 2027. Positive data advances commercialization. Yet risks linger in trial outcomes.
10-Q
Q2 FY2025 results
Compass Pathways narrowed its Q2 net loss to $38.4M from $38.1M a year earlier, while YTD net loss widened to $56.3M from $73.3M, buoyed by a $16.9M fair value gain on warrant liabilities issued in January 2025's $149.8M financing. Operating expenses held steady at $42.9M quarterly but rose 13% YTD to $92.5M, driven by higher R&D outlays for the Phase 3 TRD program, where COMP005 hit its primary endpoint in June. Cash swelled to $221.9M by quarter-end, funding operations through at least the next year, with $30.9M debt under the Hercules loan (maturing July 2027 at effective 14.8% rate) and $22.5M minimum cash covenant met. No non-GAAP metrics disclosed in the 10-Q. Yet clinical delays could still drag timelines.
8-K
Gover joins Compass board
Compass Pathways appointed Justin Gover to its board effective July 29, 2025, as a Class III director and member of the audit and risk and scientific committees, bringing his experience leading GW Pharmaceuticals to its $7 billion sale after Epidiolex approval. This bolsters expertise in scaling biopharma operations and navigating regulations for scheduled products amid Compass's Phase 3 success in treatment-resistant depression. Dr. Linda McGoldrick retires October 31 after guiding the 2020 IPO and early milestones. Gover's track record sharpens commercialization focus.
8-K
Phase 3 trial success announced
Compass Pathways hit the primary endpoint in its Phase 3 COMP005 trial for COMP360 psilocybin in treatment-resistant depression. A single 25 mg dose beat placebo on MADRS score reductions from baseline at week 6, with p<0.0001. This breakthrough advances the first of two pivotal studies. Success here bolsters regulatory hopes, yet full data await.
IPO
Website
Employees
Sector
Industry
AIBT
Aibotics Inc.
0.00+0.00
ATAI
Atai Beckley N.V
4.23+0.09
BWAY
Brainsway Ltd.
16.87-0.47
CMND
Clearmind Medicine Inc.
2.62-0.10
CMPX
Compass Therapeutics, Inc.
5.24+0.16
CYBN
Cybin Inc.
6.66+0.00
EHC
Encompass Health Corporation
108.01+0.42
ENVB
Enveric Biosciences, Inc.
5.24-0.12
LFST
LifeStance Health Group, Inc.
6.88-0.04
PBM
Psyence Biomedical Ltd.
1.53+0.05